Cogent Biosciences Stock Current Valuation
| COGT Stock | USD 9.19 0.06 0.66% |
Valuation analysis of Cogent Biosciences helps investors to measure Cogent Biosciences' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value is likely to gain to about 528.1 M in 2024, despite the fact that Enterprise Value Over EBITDA is likely to grow to (2.00). Fundamental drivers impacting Cogent Biosciences' valuation include:
Price Book 4.9748 | Enterprise Value 808.1 M | Enterprise Value Ebitda (3.89) | Price Sales 1.3 K | Enterprise Value Revenue 925.407 |
Undervalued
Today
Please note that Cogent Biosciences' price fluctuation is somewhat reliable at this time. Calculation of the real value of Cogent Biosciences is based on 3 months time horizon. Increasing Cogent Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Cogent Biosciences' intrinsic value may or may not be the same as its current market price of 9.19, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9.19 | Real 12.28 | Target 22.11 | Hype 9.2 | Naive 9.28 |
The intrinsic value of Cogent Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cogent Biosciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cogent Biosciences helps investors to forecast how Cogent stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cogent Biosciences more accurately as focusing exclusively on Cogent Biosciences' fundamentals will not take into account other important factors: Cogent Biosciences Company Current Valuation Analysis
Cogent Biosciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Cogent Biosciences Current Valuation | 808.05 M |
Most of Cogent Biosciences' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cogent Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cogent Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Cogent Biosciences is extremely important. It helps to project a fair market value of Cogent Stock properly, considering its historical fundamentals such as Current Valuation. Since Cogent Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cogent Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cogent Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Cogent Biosciences has a Current Valuation of 808.05 M. This is 94.37% lower than that of the Biotechnology sector and 82.61% lower than that of the Health Care industry. The current valuation for all United States stocks is 95.14% higher than that of the company.
Cogent Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cogent Biosciences' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cogent Biosciences could also be used in its relative valuation, which is a method of valuing Cogent Biosciences by comparing valuation metrics of similar companies.Cogent Biosciences is currently under evaluation in current valuation category among its peers.
Cogent Biosciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cogent Biosciences from analyzing Cogent Biosciences' financial statements. These drivers represent accounts that assess Cogent Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cogent Biosciences' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 21.9M | 124.4M | 332.3M | 679.0M | 611.1M | 641.7M | |
| Enterprise Value | (9.4M) | (112.5M) | 115.8M | 558.8M | 502.9M | 528.1M |
Cogent Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cogent Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cogent Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Cogent Fundamentals
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.44 | ||||
| Current Valuation | 808.05 M | ||||
| Shares Outstanding | 110.46 M | ||||
| Shares Owned By Insiders | 0.12 % | ||||
| Shares Owned By Institutions | 99.88 % | ||||
| Number Of Shares Shorted | 8.43 M | ||||
| Price To Earning | (5.03) X | ||||
| Price To Book | 4.97 X | ||||
| Price To Sales | 1,321 X | ||||
| Gross Profit | (121.63 M) | ||||
| EBITDA | (205.86 M) | ||||
| Net Income | (192.41 M) | ||||
| Cash And Equivalents | 325.56 M | ||||
| Cash Per Share | 4.95 X | ||||
| Total Debt | 18.85 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 11.96 X | ||||
| Book Value Per Share | 1.85 X | ||||
| Cash Flow From Operations | (153.62 M) | ||||
| Short Ratio | 8.79 X | ||||
| Earnings Per Share | (2.48) X | ||||
| Price To Earnings To Growth | (0.14) X | ||||
| Target Price | 16.36 | ||||
| Number Of Employees | 164 | ||||
| Beta | 0.021 | ||||
| Market Capitalization | 1.02 B | ||||
| Total Asset | 313.44 M | ||||
| Retained Earnings | (603.62 M) | ||||
| Working Capital | 232.6 M | ||||
| Current Asset | 37.62 M | ||||
| Current Liabilities | 21.06 M | ||||
| Net Asset | 313.44 M |
About Cogent Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cogent Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cogent Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cogent Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.